


1. The Progression of the IBD-U™ Initiative

A traveling center of excellence

2019 co-Chairs



Russell D. Cohen, MD, FACP, AGAF
Director,
Inflammatory Bowel Disease Center
University of Chicago Medicine



David T. Rubin, MD, FACP, AGAF, FASGE
Section Chief,
Gastroenterology,
Hepatology and Nutrition
University of Chicago Medicine
Chicago, IL

2019 APP Faculty

- Mary Ayers, BSN-RN
- Linda Kulig, RN, BFA, BSN, CGRN
- Ashley A. Bochenek, APN, FNP-BC
- Alexandra Masching, MSN, APN, FNP-BC
- Janice C. Colwell APRN, CWOCCN, FAAN
- Michele Rubin, MSN, APN, CNS, CGRN
- Sushila Dalal, MD

Unique Features



Provider tools, gamified learning, multidisciplinary panels

2016-17



Feb. 14, 2017

1,693 Learners

Topics Addressed:



Immunopathology

2017-18



Jan. 31, 2018

1,815 Learners



Treatment

2018-19



>10,000
have been educated



Communication and SDM

3. Cumulative Attendee Demographics

Degree

- MD/DO
- NP
- PA
- PharmD/RPh
- RN/BSN/MSN
- Other HCP


71%
NP or PA

Specialty

- Gastroenterology
- IBD
- Internal Medicine
- Family/General Practice
- Nursing
- Other

Practice Patterns

In what percentage of your patients with IBD do you prescribe biologic therapy?



Patients Seen



Attendees see an average of **8 patients** per month with IBD

4. Educational Impact

Impact on Patient Health

100%

Report that the activity was better than most for positively impacting patient health

Average Increase in Learning*

78%

Relative increase in knowledge and competence

Planned Practice Changes

96%

Have implemented practice changes such as implementing the latest clinical advances; **80%** of these have observed improvements in patient health

Average Patient Impact*

>6,000



Potential number of patients with IBD seen per month by participants who are **now more likely to receive evidence-based care**

Impact of Activities

*Data based on test takers.

5. Closing the Gaps - 2019

Immunopathology and Clinical Advances



- ✓ 94% relative increase in knowledge regarding **useful diagnostic tests for CD**
- ✓ 78% relative increase in knowledge regarding **treatment**
- ✓ 76% relative increase in knowledge regarding **indications for vedolizumab**
- ✓ 96% plan to **incorporate medical advances** into clinical decision making, if not already doing so

Engaging Patients



- ✓ Post-learning, 97% were aware of how to counsel patients regarding hesitation to start treatment
- ✓ 98% plan to engage in appropriate **multidisciplinary care**, if not already doing so
- ✓ 97% would **appropriately counsel patients** on dietary habits

5. Application to Future Programs

Persisting Needs




- ✓ Knowledge and confidence was more discordant on the topic of diagnosis
- ✓ Attendees lack consensus on when to switch to a new biologic vs intensifying TNFi treatment
- ✓ Knowledge is lacking regarding assessment of risk in patients being treated for IBD

Planned 2019-2020 Initiative



Relevant Cases



Refined recruitment

"Best Of" Web Posting



Multidisciplinary panels

